Connection

David Taber to Graft Rejection

Back to Details
This is a "connection" page, showing publications David Taber has written about Graft Rejection.
David Taber
Connection Strength
10.084
Graft Rejection
  1. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Ann Pharmacother. 2020 12; 54(12):1185-1193.
    View in: PubMed
    Score: 0.536
  2. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients. Clin Transplant. 2019 10; 33(10):e13679.
    View in: PubMed
    Score: 0.509
  3. Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race. Exp Clin Transplant. 2019 12; 17(6):707-713.
    View in: PubMed
    Score: 0.484
  4. Renal Function Variability: An Independent Risk Factor for Graft Loss and Death following Kidney Transplantation. Am J Nephrol. 2018; 47(3):191-199.
    View in: PubMed
    Score: 0.459
  5. Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients. Ann Transplant. 2018 Feb 16; 23:119-128.
    View in: PubMed
    Score: 0.456
  6. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Ann Surg. 2017 09; 266(3):450-456.
    View in: PubMed
    Score: 0.442
  7. Ambulatory Care Coordination Issues With Dual Use Veteran Organ Transplant Recipients. Prog Transplant. 2017 06; 27(2):187-191.
    View in: PubMed
    Score: 0.429
  8. The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation. Am J Nephrol. 2017; 45(1):91-98.
    View in: PubMed
    Score: 0.420
  9. African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy. 2015 Jun; 35(6):569-77.
    View in: PubMed
    Score: 0.378
  10. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. Clin Transplant. 2015 Mar; 29(3):222-6.
    View in: PubMed
    Score: 0.369
  11. Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation. J Pharm Pract. 2016 Apr; 29(2):97-102.
    View in: PubMed
    Score: 0.357
  12. Cardiovascular risk factors contribute to disparities in graft outcomes in African American renal transplant recipients: a retrospective analysis. Blood Press. 2015 Feb; 24(1):14-22.
    View in: PubMed
    Score: 0.356
  13. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. Am J Nephrol. 2014; 40(1):19-28.
    View in: PubMed
    Score: 0.355
  14. Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation. Clin Transplant. 2013 Mar-Apr; 27(2):274-82.
    View in: PubMed
    Score: 0.322
  15. The impact of diabetes on ethnic disparities seen in kidney transplantation. Ethn Dis. 2013; 23(2):238-44.
    View in: PubMed
    Score: 0.320
  16. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation. 2005 Dec 15; 80(11):1633-5.
    View in: PubMed
    Score: 0.196
  17. Evaluation of estimated and measured creatinine clearances for predicting the pharmacokinetics of vancomycin in adult liver transplant recipients. Ther Drug Monit. 2003 Feb; 25(1):67-72.
    View in: PubMed
    Score: 0.161
  18. A viewpoint describing the American Society of Transplantation rationale to conduct a comprehensive patient survey assessing unmet immunosuppressive therapy needs. Clin Transplant. 2023 03; 37(3):e14876.
    View in: PubMed
    Score: 0.159
  19. Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2021 10; 16(10):1539-1551.
    View in: PubMed
    Score: 0.147
  20. Impact of a pharmacist-led, mHealth-based intervention on tacrolimus trough variability in kidney transplant recipients: A report from the TRANSAFE Rx randomized controlled trial. Am J Health Syst Pharm. 2021 07 09; 78(14):1287-1293.
    View in: PubMed
    Score: 0.144
  21. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Ther Drug Monit. 2021 06 01; 43(3):401-407.
    View in: PubMed
    Score: 0.143
  22. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant. 2020 08; 20(8):1969-1983.
    View in: PubMed
    Score: 0.134
  23. Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: Results of a randomized controlled pilot study. Clin Transplant. 2020 04; 34(4):e13844.
    View in: PubMed
    Score: 0.132
  24. Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients-A single-center experience with a large African American population. Clin Transplant. 2019 10; 33(10):e13701.
    View in: PubMed
    Score: 0.127
  25. Long-standing diabetes mellitus and pancreas transplantation: An avenue to increase utilization of an ideal treatment modality. Clin Transplant. 2019 10; 33(10):e13695.
    View in: PubMed
    Score: 0.127
  26. Using informatics and mobile health to improve medication safety monitoring in kidney transplant recipients. Am J Health Syst Pharm. 2019 Jul 18; 76(15):1143-1149.
    View in: PubMed
    Score: 0.126
  27. Development and future deployment of a 5 years allograft survival model for kidney transplantation. Nephrology (Carlton). 2019 Aug; 24(8):855-862.
    View in: PubMed
    Score: 0.124
  28. The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transpl Int. 2019 01; 32(1):84-94.
    View in: PubMed
    Score: 0.119
  29. Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types. Transplantation. 2018 09; 102(9):1440-1452.
    View in: PubMed
    Score: 0.118
  30. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017 12; 101(12):2931-2938.
    View in: PubMed
    Score: 0.112
  31. Morbid obesity and functional status as predictors of surgical complication after renal transplantation. Am J Surg. 2018 Apr; 215(4):663-668.
    View in: PubMed
    Score: 0.109
  32. A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2017 01 06; 12(1):131-139.
    View in: PubMed
    Score: 0.105
  33. Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients. Am J Surg. 2017 Apr; 213(4):666-672.
    View in: PubMed
    Score: 0.105
  34. Twenty years of evolving trends in racial disparities for adult kidney transplant recipients. Kidney Int. 2016 10; 90(4):878-87.
    View in: PubMed
    Score: 0.103
  35. Yes, We Still Need IL-2 Receptor Antagonists. Am J Transplant. 2016 11; 16(11):3308-3309.
    View in: PubMed
    Score: 0.102
  36. Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients. Transplantation. 2016 07; 100(7):1550-7.
    View in: PubMed
    Score: 0.102
  37. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients. Clin Transplant. 2016 05; 30(5):528-33.
    View in: PubMed
    Score: 0.100
  38. Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes? Medicine (Baltimore). 2015 Dec; 94(49):e2283.
    View in: PubMed
    Score: 0.098
  39. Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients. Pediatr Transplant. 2015 Aug; 19(5):555-62.
    View in: PubMed
    Score: 0.094
  40. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014 May; 259(5):888-93.
    View in: PubMed
    Score: 0.088
  41. Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients. Ther Drug Monit. 2013 Dec; 35(6):753-9.
    View in: PubMed
    Score: 0.085
  42. Improving transplant patient safety through pharmacist discharge medication reconciliation. Am J Transplant. 2013 Mar; 13(3):796-801.
    View in: PubMed
    Score: 0.080
  43. The impact of cardiovascular disease and risk factor treatment on ethnic disparities in kidney transplant. J Cardiovasc Pharmacol Ther. 2013 May; 18(3):243-50.
    View in: PubMed
    Score: 0.080
  44. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients. Transplant Proc. 2012 Jun; 44(5):1323-8.
    View in: PubMed
    Score: 0.077
  45. A critical analysis of racial difference with mycophenolate mofetil (MMF) dosing, clinical outcomes and adverse effects in pediatric kidney transplant patients. Clin Transplant. 2011 Jul-Aug; 25(4):534-40.
    View in: PubMed
    Score: 0.067
  46. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Clin Transplant. 2010 Jan-Feb; 24(1):40-7.
    View in: PubMed
    Score: 0.061
  47. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother. 2008 Jan; 42(1):116-20.
    View in: PubMed
    Score: 0.056
  48. The impact of race on metabolic, graft, and patient outcomes after pancreas transplantation. Am J Surg. 2022 04; 223(4):812-816.
    View in: PubMed
    Score: 0.036
  49. Impact of Anesthesiologist Experience on Early Outcomes in Adult Orthotopic Liver Transplantation. Transplant Proc. 2021 Jun; 53(5):1665-1669.
    View in: PubMed
    Score: 0.036
  50. Phenotype of immunosuppression reduction after kidney transplantation. Clin Transplant. 2020 10; 34(10):e14047.
    View in: PubMed
    Score: 0.034
  51. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
    View in: PubMed
    Score: 0.028
  52. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching. Exp Clin Transplant. 2017 Feb; 15(1):47-55.
    View in: PubMed
    Score: 0.025
  53. Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. Pediatr Transplant. 2016 Feb; 20(1):44-8.
    View in: PubMed
    Score: 0.024
  54. Inflammatory biomarkers, glycemic variability, hypoglycemia, and renal transplant outcomes: results of a randomized controlled trial. Transplantation. 2014 Sep 27; 98(6):632-9.
    View in: PubMed
    Score: 0.023
  55. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. Clin Transplant. 2014 Aug; 28(8):862-8.
    View in: PubMed
    Score: 0.022
  56. Clinical and economic analysis of delayed administration of antithymocyte globulin for induction therapy in kidney transplantation. Prog Transplant. 2013 Mar; 23(1):33-8.
    View in: PubMed
    Score: 0.020
  57. Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother. 2010 Jul-Aug; 44(7-8):1259-70.
    View in: PubMed
    Score: 0.017
  58. Potential differences in kidney allograft outcomes between ethnicities when converting to sirolimus base immunosuppression. Transplant Proc. 2009 Dec; 41(10):4131-7.
    View in: PubMed
    Score: 0.016
  59. Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transpl Int. 2010 May 01; 23(5):500-5.
    View in: PubMed
    Score: 0.016
  60. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplantation. 2004 Aug 27; 78(4):619-22.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.